June 2019 - Cancer Currents Blog
-
Trial Highlights Complexities of Targeted Therapy for Pancreatic CancerOlaparib (Lynparza) may be beneficial for some people with advanced pancreatic cancer who have inherited mutations in the BRCA1 or BRCA2 genes, according to results from the POLO trial.
-
More Treatment Options Emerging for Some Men with Metastatic Prostate CancerIn two large clinical trials, the drugs enzalutamide (Xtandi) and apalutamide (Erleada), respectively, combined with the androgen deprivation therapy, improved the survival of men with metastatic prostate cancer that still responds to hormone-suppressing therapies.
-
Combination Therapy with Venetoclax Approved for Chronic Lymphocytic LeukemiaThe Food and Drug Administration has approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
-
Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer CellsResearchers have discovered a potential way to turn on one of the most commonly silenced tumor-suppressor proteins in cancer, called PTEN. They also found a natural compound, I3C, that in lab studies could flip the on switch.
-
The Childhood Cancer Data Initiative: Why Data Sharing Is Essential to ProgressNCI is laying the groundwork to develop the Childhood Cancer Data Initiative (CCDI). NCI Acting Director Douglas Lowy, M.D., explains why an initiative with a focus on data sharing is essential to accelerating progress against childhood cancer.
-
Drug Shows Promise in Slowing Progression of Smoldering Myeloma to CancerThe drug lenalidomide (Revlimid) may delay the progression of smoldering myeloma to multiple myeloma, according to preliminary results from a clinical trial.